UNSPSC 51273922: Bupivacaine/dextrose/epinephrine/lidocaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273922 Bupivacaine/dextrose/epinephrine/lidocaine is a Commodity code that maps to state and local procurement of pharmaceutical and medical products, though recent opportunities under this code tag show substantial misalignment with the narrow anesthetic-formulation scope the code name suggests. State and local buyers posting under this code are actually soliciting broad pharmaceutical supply contracts—generic multi-source drugs, over-the-counter products, naloxone, and pharmacy benefit program administration—rather than specialty injectable anesthetics. The issuing bodies include state health and human services departments, county health systems, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and participating agencies. Scope varies from direct-to-manufacturer prescription programs designed to bypass pharmacy benefit managers, to annual bulk purchases of naloxone and drug deactivation systems for community health support, to generic pharmaceutical and OTC product supply through established wholesaler networks.

Recent activity spans Florida, Texas, and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP posted January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to work through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with pricing weighted at 75 percent of evaluation and a two-year initial contract term. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026 with a July 26, 2023 due date for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and optional one-year renewal. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, designed to gather market intelligence before issuing formal competitive solicitation. The code shows active, multi-state procurement activity, though the recent opportunities reflect broader pharmaceutical supply and program management work rather than the specific anesthetic formulation the code nominally describes.